Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
2024-515490-10-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of elotuzumab in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Primary endpoint: Number of subjects who received at least one dose of elotuzumab or backbone therapy and duration of treatment. Started Aug 2024; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-515490-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515490-10-00.